Third Harmonic Bio, Inc. (THRD) Price & Analysis

Compare

32 Followers

THRD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.18 - $16.02

Previous CloseN/A

Volume85.60K

Average Volume (3M)240.99K

Market Cap

$242.79M

Enterprise Value-$112.75M

Total Cash (Recent Filing)$271.61M

Total Debt (Recent Filing)$3.00M

Price to Earnings (P/E)―

Beta-0.04

Next Earnings

Aug 07, 2025

EPS Estimate

-0.23

Last Dividend Ex-Date

Aug 06, 2014

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding45,128,000

10 Day Avg. Volume372,220

30 Day Avg. Volume240,992

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-0.46

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit9.40K

Enterprise Value/Ebitda1.79

Forecast

1Y Price Target

$5.23

Price Target Upside-2.79% Downside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Financial ResourcesThird Harmonic ended the fourth quarter of 2024 with $285 million in cash, which is expected to support operations at least through 2026.

Research And DevelopmentTHB335 demonstrated strong pharmacokinetics and pharmacodynamics with deep serum tryptase reductions.

Research OpportunitiesThere may be an opportunity to evaluate THB335 at moderate doses in patients with mast cell-mediated disorders such as chronic spontaneous urticaria.

Bears Say

Company StrategyThird Harmonic Bio announced plans to liquidate and dissolve the company.

Safety ConcernsSafety concerns from Phase 1 data, including reductions in hemoglobin and neutrophils, likely limit the use of higher doses of THB335.

Stock RatingThe stock rating for THRD has been downgraded to Hold due to a lack of clarity on the development path for THB335.

Third Harmonic Bio, Inc. News

Third Harmonic Bio to Delist from Nasdaq

Third Harmonic Bio, Inc. ( ($THRD) ) has issued an announcement. On July 31, 2025, Third Harmonic Bio,...

12d ago

THRD

Third Harmonic Bio Plans Nasdaq Delisting by July 31

Third Harmonic Bio, Inc. ( ($THRD) ) has issued an announcement. Third Harmonic Bio, Inc. announced its intention...

23d ago

THRD

Third Harmonic Bio Approves Liquidation and Dissolution Plan

The latest update is out from Third Harmonic Bio, Inc. ( ($THRD) ). Third Harmonic Bio, Inc. announced...

2M ago

THRD

Third Harmonic Bio receives stockholder approval of plan of liquidation

Third Harmonic Bio (THRD) announced that its stockholders overwhelmingly approved the previously proposed Plan of Liquidation and Dissolution...

2M ago

THRD

Third Harmonic Bio reports updated THB335 data, initiates THB335 sale

As part of the previously announced ongoing Phase 2 readiness activities, the Company recently completed an additional 14-day...

2M ago

THRD

Third Harmonic Bio Approves Key Proposals at Annual Meeting

An announcement from Third Harmonic Bio, Inc. ( ($THRD) ) is now available. On June 5, 2025, Third...

2M ago

THRD

Third Harmonic Bio Reports Q1 2025 Financial Results

Third Harmonic Bio, Inc. ( ($THRD) ) has released its Q1 earnings. Here is a breakdown of the...

2M ago

THRD

Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down

Third Harmonic Bio, Inc. ( ($THRD) ) has provided an announcement. On April 21, 2025, Third Harmonic Bio,...

4M ago

THRD

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

PTN

ARTL

Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties

In a report released yesterday, Michael Ulz from Morgan Stanley maintained a Hold rating on Third Harmonic Bio,...

4M ago

THRD

Third Harmonic Bio sees initial distribution of $5.13-$5.33 from liquidation

On April 10, the Board of Directors unanimously approved the dissolution and liquidation of the Company, subject to...

4M ago

THRD

Third Harmonic Bio announces plan of liquidation and dissolution

Third Harmonic Bio (THRD) announced that the company’s board of directors, after considering opportunities to maximize stockholder value,...

4M ago

THRD

Hold Rating for Third Harmonic Bio, Inc. Amid Strategic Exploration and Cautious Development Approach

Morgan Stanley analyst Michael Ulz has reiterated their neutral stance on THRD stock, giving a Hold rating yesterday....

5M ago

THRD

Third Harmonic Bio Reports 2024 Financial Results and Strategic Plans

Third Harmonic Bio, Inc. ( ($THRD) ) has released its Q4 earnings. Here is a breakdown of the...

5M ago

THRD

THRD FAQ

What was Third Harmonic Bio, Inc.’s price range in the past 12 months?

Third Harmonic Bio, Inc. lowest stock price was $3.18 and its highest was $16.02 in the past 12 months.

What is Third Harmonic Bio, Inc.’s market cap?

Third Harmonic Bio, Inc.’s market cap is $242.79M.

When is Third Harmonic Bio, Inc.’s upcoming earnings report date?

Third Harmonic Bio, Inc.’s upcoming earnings report date is Aug 07, 2025 which is 6 days ago.

How were Third Harmonic Bio, Inc.’s earnings last quarter?

Third Harmonic Bio, Inc. released its earnings results on May 08, 2025. The company reported -$0.352 earnings per share for the quarter, missing the consensus estimate of -$0.245 by -$0.107.

Is Third Harmonic Bio, Inc. overvalued?

According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Third Harmonic Bio, Inc. pay dividends?

Third Harmonic Bio, Inc. pays a Quarterly dividend of $0.12 which represents an annual dividend yield of N/A. See more information on Third Harmonic Bio, Inc. dividends here

What is Third Harmonic Bio, Inc.’s EPS estimate?

Third Harmonic Bio, Inc.’s EPS estimate is -0.23.

How many shares outstanding does Third Harmonic Bio, Inc. have?

Third Harmonic Bio, Inc. has 45,128,000 shares outstanding.

What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?

Third Harmonic Bio, Inc. reported an EPS of -$0.352 in its last earnings report, missing expectations of -$0.245. Following the earnings report the stock price went up 0.195%.

Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?

Currently, no hedge funds are holding shares in THRD

Third Harmonic Bio, Inc. Stock Smart Score

Underperform

Fundamentals

Return on Equity

-19.94%

Trailing 12-Months

Asset Growth

3.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Third Harmonic Bio, Inc.

Third Harmonic Bio, Inc. (THRD) is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of allergic and inflammatory diseases. Leveraging its expertise in immunology and drug development, the company aims to address unmet medical needs by creating targeted therapies that modulate specific pathways involved in allergic and inflammatory responses.